RxDoctor Payments Data

Robert Franchi, DO

Ophthalmology · Clinton Township, MINPI 1003903071

Payments from drug & device makers

$3,196in general payments, 2019–2025

Across 81 payments — averaging $39.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Bausch & Lomb Americas Inc.$618
  • Eyevance Pharmaceuticals LLC$265
  • Kala Pharmaceuticals, Inc.$203
  • Carl Zeiss Meditec USA, Inc.$189
  • Aerie Pharmaceuticals, Inc.$157
  • plus $555 from 9 others

What the payments were for

  • Travel & lodging$41313%
  • Food & beverage$2,78287%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,196 in reported general payments places this provider in the 70th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$324,175
Medicare patients
629
Services billed
3,063

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost31$19,222
Bromfenac Sodium52$11,726
Difluprednate155$10,361
Tobradex StTobramycin/Dexamethasone38$8,638
Latanoprost291$8,319
ProlensaBromfenac Sodium24$8,175
Travoprost33$7,087
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$6,944
CombiganBrimonidine Tartrate/Timolol12$6,391
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat131$3,508
Timolol Maleate175$3,369
Dorzolamide-TimololDorzolamide/Timolol/Pf20$3,057
MoxifloxacinMoxifloxacin Hcl232$2,969
Brimonidine Tartrate37$2,553
Dorzolamide Hcl46$1,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$68$25,61343 claims
Eyevance Pharmaceuticals LLCTobradex St$265$8,63838 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$38$8,17524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Clinton Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →